<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>10(41)</volume><submitter>Lee Y</submitter><pubmed_abstract>Oral delivery of cannabidiol (CBD) is challenging because of its poor water solubility and low bioavailability, which restrict its therapeutic potential. In this study, we used a CBD-loaded oil-in-water nanoemulsion prepared from octenyl succinate anhydride (OSA)-modified starch to address these challenges. The CBD-encapsulated nanoemulsion (CBD-NE) exhibited a uniform particle size of 39.18 ± 0.15 nm, high encapsulation efficiency of 99.80 ± 0.13%, and maintained colloidal stability during storage for 28 days. Simulated gastrointestinal digestion demonstrated that the bioaccessibility of CBD in CBD-NE was higher than that in unformulated CBD. Furthermore, &lt;i>in vitro&lt;/i> experiments using RAW264.7 macrophages showed that CBD-NE significantly (&lt;i>p&lt;/i> &lt; 0.05) suppressed lipopolysaccharide</pubmed_abstract><journal>ACS omega</journal><pagination>48146-48154</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12573299</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Cannabidiol Loaded Nanoemulsion with Improved Bioaccessibility and Anti-Inflammatory Activity.</pubmed_title><pmcid>PMC12573299</pmcid><pubmed_authors>Song HY</pubmed_authors><pubmed_authors>Kim SH</pubmed_authors><pubmed_authors>Byun EB</pubmed_authors><pubmed_authors>Lee Y</pubmed_authors></additional><is_claimable>false</is_claimable><name>Cannabidiol Loaded Nanoemulsion with Improved Bioaccessibility and Anti-Inflammatory Activity.</name><description>Oral delivery of cannabidiol (CBD) is challenging because of its poor water solubility and low bioavailability, which restrict its therapeutic potential. In this study, we used a CBD-loaded oil-in-water nanoemulsion prepared from octenyl succinate anhydride (OSA)-modified starch to address these challenges. The CBD-encapsulated nanoemulsion (CBD-NE) exhibited a uniform particle size of 39.18 ± 0.15 nm, high encapsulation efficiency of 99.80 ± 0.13%, and maintained colloidal stability during storage for 28 days. Simulated gastrointestinal digestion demonstrated that the bioaccessibility of CBD in CBD-NE was higher than that in unformulated CBD. Furthermore, &lt;i>in vitro&lt;/i> experiments using RAW264.7 macrophages showed that CBD-NE significantly (&lt;i>p&lt;/i> &lt; 0.05) suppressed lipopolysaccharide</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Oct</publication><modification>2026-06-05T09:43:00.588Z</modification><creation>2026-05-15T03:12:57.913Z</creation></dates><accession>S-EPMC12573299</accession><cross_references><pubmed>41180072</pubmed><doi>10.1021/acsomega.5c04608</doi></cross_references></HashMap>